Page last updated: 2024-08-24

adenosine and acp-196

adenosine has been researched along with acp-196 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Chen, SS; Chiorazzi, N; Covey, T; Dadashian, EL; Herman, SEM; Izumi, R; Krantz, F; Lannutti, BJ; Mora-Jensen, HI; Niemann, CU; Ulrich, R; Wiestner, A	1
Bernasconi, E; Bertoni, F; Cascione, L; Dirnhofer, S; Gaudio, E; Gerlach, MM; Mascia, M; Priebe, V; Spriano, F; Stathis, A; Tarantelli, C; Targa, A; Zucca, E	1
Barr, PM; Calvo, R; Melear, JM; O'Brien, SM; Patel, P; Roschewski, MJ; Sharman, JP; Smith, SD; Spurgeon, SE; Yang, H	1

Trials

1 trial(s) available for adenosine and acp-196

Article	Year
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia & lymphoma, 2022, Volume: 63, Issue:7 Topics: Adenosine; Benzamides; Humans; Lymphoma, B-Cell; Phosphatidylinositol 3-Kinases; Pyrazines; Quinolines	2022

Other Studies

2 other study(ies) available for adenosine and acp-196

Article	Year
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-01, Volume: 23, Issue:19 Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cell Proliferation; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tumor Microenvironment	2017
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. British journal of haematology, 2019, Volume: 187, Issue:5 Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019

Article

Year

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-01, Volume: 23, Issue:19

Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cell Proliferation; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tumor Microenvironment

2017

Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.

British journal of haematology, 2019, Volume: 187, Issue:5

Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019